Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progres
Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung CancerCompany Secured up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Thr...
Source: pharmiweb.com